Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
[Leukaemic phase of Mantle zone (intermediate) lymphoma--case report--].

Srpski arhiv za celokupno lekarstvo

Vidović A, Suvajcić N, Jovanović V, Janković G.
PMID: 17972826
Srp Arh Celok Lek. 1994 Mar-Apr;122(3):113-5.

Leukaemic phase of non-Hodgkin lymphoma (NHL) is characterised by penetration of lymphoma cells from the originating tissues (lymph nodes, less commonly the spleen) into the peripheral blood and bone marrow. The diagnosis of leukaemic phase of Mantle zone lymphoma...

Cite
Vidović A, Suvajcić N, Jovanović V, et al. Leukemijska faza intermdijarnog ("mantl-zon") limfoma--prikaz bolesnika. [Leukaemic phase of Mantle zone (intermediate) lymphoma--case report--]. Srp Arh Celok Lek. 1994;122(3):113-5
Vidović, A., Suvajcić, N., Jovanović, V., & Janković, G. (1994). Leukemijska faza intermdijarnog ("mantl-zon") limfoma--prikaz bolesnika. [Leukaemic phase of Mantle zone (intermediate) lymphoma--case report--]. Srpski arhiv za celokupno lekarstvo, 122(3), 113-5.
Vidović, A, et al. "Leukemijska faza intermdijarnog ("mantl-zon") limfoma--prikaz bolesnika." [Leukaemic phase of Mantle zone (intermediate) lymphoma--case report--]. Srpski arhiv za celokupno lekarstvo vol. 122,3 (1994): 113-5.
Vidović A, Suvajcić N, Jovanović V, Janković G. Leukemijska faza intermdijarnog ("mantl-zon") limfoma--prikaz bolesnika. [Leukaemic phase of Mantle zone (intermediate) lymphoma--case report--]. Srp Arh Celok Lek. 1994 Mar-Apr;122(3):113-5. Serbian. PMID: 17972826.
Copy Download .nbib Format: NLM
Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?.

Seminars in hematology

Dreyling M.
PMID: 21782055
Semin Hematol. 2011 Jul;48(3):145-7. doi: 10.1053/j.seminhematol.2011.06.003.

No abstract available.

Cite
Dreyling M. Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?. Semin Hematol. 2011;48(3):145-7doi: 10.1053/j.seminhematol.2011.06.003.
Dreyling, M. (2011). Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?. Seminars in hematology, 48(3), 145-7. https://doi.org/10.1053/j.seminhematol.2011.06.003
Dreyling, Martin. "Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?." Seminars in hematology vol. 48,3 (2011): 145-7. doi: https://doi.org/10.1053/j.seminhematol.2011.06.003
Dreyling M. Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?. Semin Hematol. 2011 Jul;48(3):145-7. doi: 10.1053/j.seminhematol.2011.06.003. PMID: 21782055.
Copy Download .nbib Format: NLM
Open questions in the management of mantle cell lymphoma.

Cancer treatment reviews

Li ZM, Zucca E, Ghielmini M.
PMID: 23415066
Cancer Treat Rev. 2013 Oct;39(6):602-9. doi: 10.1016/j.ctrv.2012.12.013. Epub 2013 Feb 13.

Mantle cell lymphoma (MCL) is one of the lymphomas with the worse prognosis (median survival 3-5years) as it has an aggressive evolution and at the same time is incurable. Biologically it is characterized by the t(11;14)(q13;q32) translocation leading to...

Cite
Li ZM, Zucca E, Ghielmini M. Open questions in the management of mantle cell lymphoma. Cancer Treat Rev. 2013;39(6):602-9doi: 10.1016/j.ctrv.2012.12.013.
Li, Z. M., Zucca, E., & Ghielmini, M. (2013). Open questions in the management of mantle cell lymphoma. Cancer treatment reviews, 39(6), 602-9. https://doi.org/10.1016/j.ctrv.2012.12.013
Li, Zhi-Ming, et al. "Open questions in the management of mantle cell lymphoma." Cancer treatment reviews vol. 39,6 (2013): 602-9. doi: https://doi.org/10.1016/j.ctrv.2012.12.013
Li ZM, Zucca E, Ghielmini M. Open questions in the management of mantle cell lymphoma. Cancer Treat Rev. 2013 Oct;39(6):602-9. doi: 10.1016/j.ctrv.2012.12.013. Epub 2013 Feb 13. PMID: 23415066.
Copy Download .nbib Format: NLM
Radiotherapy in mantle cell lymphoma: A literature review.

Hematological oncology

Ben Barouch S, Kuruvilla J, Tsang RW, Yashphe E, Sarid N.
PMID: 31873945
Hematol Oncol. 2020 Aug;38(3):223-228. doi: 10.1002/hon.2708. Epub 2020 Feb 19.

Mantle cell lymphoma (MCL) is a B-cell malignancy, comprising between 3% and 10% of all adult-onset non-Hodgkin lymphomas. MCL is considered incurable with current treatment modalities and most patients require multiple lines of treatment during their lifetime. MCL is...

Cite
Ben Barouch S, Kuruvilla J, Tsang RW, et al. Radiotherapy in mantle cell lymphoma: A literature review. Hematol Oncol. 2020;38(3):223-228doi: 10.1002/hon.2708.
Ben Barouch, S., Kuruvilla, J., Tsang, R. W., Yashphe, E., & Sarid, N. (2020). Radiotherapy in mantle cell lymphoma: A literature review. Hematological oncology, 38(3), 223-228. https://doi.org/10.1002/hon.2708
Ben Barouch, Sharon, et al. "Radiotherapy in mantle cell lymphoma: A literature review." Hematological oncology vol. 38,3 (2020): 223-228. doi: https://doi.org/10.1002/hon.2708
Ben Barouch S, Kuruvilla J, Tsang RW, Yashphe E, Sarid N. Radiotherapy in mantle cell lymphoma: A literature review. Hematol Oncol. 2020 Aug;38(3):223-228. doi: 10.1002/hon.2708. Epub 2020 Feb 19. PMID: 31873945.
Copy Download .nbib Format: NLM
[Clinical features and treatment analysis of mantle cell lymphoma].

Zhonghua zhong liu za zhi [Chinese journal of oncology]

Wei N, Shen J, Wang J, Huang D, Fu L, Wu L, Cui H, Yang L, Wang Z.
PMID: 26887522
Zhonghua Zhong Liu Za Zhi. 2015 Nov;37(11):873-4.

No abstract available.

Cite
Wei N, Shen J, Wang J, et al. [Clinical features and treatment analysis of mantle cell lymphoma]. Zhonghua Zhong Liu Za Zhi. 2015;37(11):873-4
Wei, N., Shen, J., Wang, J., Huang, D., Fu, L., Wu, L., Cui, H., Yang, L., & Wang, Z. (2015). [Clinical features and treatment analysis of mantle cell lymphoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 37(11), 873-4.
Wei, Na, et al. "[Clinical features and treatment analysis of mantle cell lymphoma]." Zhonghua zhong liu za zhi [Chinese journal of oncology] vol. 37,11 (2015): 873-4.
Wei N, Shen J, Wang J, Huang D, Fu L, Wu L, Cui H, Yang L, Wang Z. [Clinical features and treatment analysis of mantle cell lymphoma]. Zhonghua Zhong Liu Za Zhi. 2015 Nov;37(11):873-4. Chinese. PMID: 26887522.
Copy Download .nbib Format: NLM
Limited-stage mantle cell lymphoma: not so different from advanced-stage.

Leukemia & lymphoma

Martin P, Shah B.
PMID: 22988842
Leuk Lymphoma. 2013 Feb;54(2):217-8. doi: 10.3109/10428194.2012.731053. Epub 2012 Oct 16.

No abstract available.

Cite
Martin P, Shah B. Limited-stage mantle cell lymphoma: not so different from advanced-stage. Leuk Lymphoma. 2012;54(2):217-8doi: 10.3109/10428194.2012.731053.
Martin, P., & Shah, B. (2013). Limited-stage mantle cell lymphoma: not so different from advanced-stage. Leukemia & lymphoma, 54(2), 217-8. https://doi.org/10.3109/10428194.2012.731053
Martin, Peter, and Shah, Bijal. "Limited-stage mantle cell lymphoma: not so different from advanced-stage." Leukemia & lymphoma vol. 54,2 (2013): 217-8. doi: https://doi.org/10.3109/10428194.2012.731053
Martin P, Shah B. Limited-stage mantle cell lymphoma: not so different from advanced-stage. Leuk Lymphoma. 2013 Feb;54(2):217-8. doi: 10.3109/10428194.2012.731053. Epub 2012 Oct 16. PMID: 22988842.
Copy Download .nbib Format: NLM
Case report: blastic Mantle Cell Leukemia.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Bilgir O, Bilgir F, Eliyatkin N, Calan M, Ercan IA, Isikyakar T, Sari F.
PMID: 21855414
Transfus Apher Sci. 2011 Oct;45(2):157-60. doi: 10.1016/j.transci.2011.07.010. Epub 2011 Aug 19.

The patient, who was being followed up for Mantle Cell Lymphoma, was diagnosed with Mast Cell Leukemia 2 years after receiving R-CHOP treatment. The results of flow cytometry, which was performed upon determining leucocytosis and detecting blasts in the...

Cite
Bilgir O, Bilgir F, Eliyatkin N, et al. Case report: blastic Mantle Cell Leukemia. Transfus Apher Sci. 2011;45(2):157-60doi: 10.1016/j.transci.2011.07.010.
Bilgir, O., Bilgir, F., Eliyatkin, N., Calan, M., Ercan, I. A., Isikyakar, T., & Sari, F. (2011). Case report: blastic Mantle Cell Leukemia. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 45(2), 157-60. https://doi.org/10.1016/j.transci.2011.07.010
Bilgir, Oktay, et al. "Case report: blastic Mantle Cell Leukemia." Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis vol. 45,2 (2011): 157-60. doi: https://doi.org/10.1016/j.transci.2011.07.010
Bilgir O, Bilgir F, Eliyatkin N, Calan M, Ercan IA, Isikyakar T, Sari F. Case report: blastic Mantle Cell Leukemia. Transfus Apher Sci. 2011 Oct;45(2):157-60. doi: 10.1016/j.transci.2011.07.010. Epub 2011 Aug 19. PMID: 21855414.
Copy Download .nbib Format: NLM
Watch and Wait in Mantle Cell Lymphoma.

Hematology/oncology clinics of North America

Lee C, Martin P.
PMID: 32861281
Hematol Oncol Clin North Am. 2020 Oct;34(5):837-847. doi: 10.1016/j.hoc.2020.06.002. Epub 2020 Jul 29.

Mantle cell lymphoma (MCL) is a biologically heterogeneous disease, and patients may experience a clinical course ranging from indolent to very aggressive. Observational studies suggest that a subset of patients can be safely observed for a period of months...

Cite
Lee C, Martin P. Watch and Wait in Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020;34(5):837-847doi: 10.1016/j.hoc.2020.06.002.
Lee, C., & Martin, P. (2020). Watch and Wait in Mantle Cell Lymphoma. Hematology/oncology clinics of North America, 34(5), 837-847. https://doi.org/10.1016/j.hoc.2020.06.002
Lee, Christina, and Martin, Peter. "Watch and Wait in Mantle Cell Lymphoma." Hematology/oncology clinics of North America vol. 34,5 (2020): 837-847. doi: https://doi.org/10.1016/j.hoc.2020.06.002
Lee C, Martin P. Watch and Wait in Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020 Oct;34(5):837-847. doi: 10.1016/j.hoc.2020.06.002. Epub 2020 Jul 29. PMID: 32861281.
Copy Download .nbib Format: NLM
The use of microarray technologies in mantle cell lymphoma.

Seminars in hematology

Ratsch BA, Grau M, Dörken B, Lenz P, Lenz G.
PMID: 21782058
Semin Hematol. 2011 Jul;48(3):166-71. doi: 10.1053/j.seminhematol.2011.03.007.

Mantle cell lymphoma (MCL) is characterized by adverse prognosis and the development of novel therapeutic approaches is essential to improve outcome. The introduction of gene expression profiling using DNA microarrays has significantly enhanced our understanding of the molecular pathogenesis...

Cite
Ratsch BA, Grau M, Dörken B, et al. The use of microarray technologies in mantle cell lymphoma. Semin Hematol. 2011;48(3):166-71doi: 10.1053/j.seminhematol.2011.03.007.
Ratsch, B. A., Grau, M., Dörken, B., Lenz, P., & Lenz, G. (2011). The use of microarray technologies in mantle cell lymphoma. Seminars in hematology, 48(3), 166-71. https://doi.org/10.1053/j.seminhematol.2011.03.007
Ratsch, Boris A, et al. "The use of microarray technologies in mantle cell lymphoma." Seminars in hematology vol. 48,3 (2011): 166-71. doi: https://doi.org/10.1053/j.seminhematol.2011.03.007
Ratsch BA, Grau M, Dörken B, Lenz P, Lenz G. The use of microarray technologies in mantle cell lymphoma. Semin Hematol. 2011 Jul;48(3):166-71. doi: 10.1053/j.seminhematol.2011.03.007. PMID: 21782058.
Copy Download .nbib Format: NLM
Sinus-confined involvement pattern of mantle cell lymphoma.

International journal of hematology

Karube K, Todoroki J.
PMID: 31289998
Int J Hematol. 2019 Sep;110(3):263-264. doi: 10.1007/s12185-019-02695-x. Epub 2019 Jul 09.

No abstract available.

Cite
Karube K, Todoroki J. Sinus-confined involvement pattern of mantle cell lymphoma. Int J Hematol. 2019;110(3):263-264doi: 10.1007/s12185-019-02695-x.
Karube, K., & Todoroki, J. (2019). Sinus-confined involvement pattern of mantle cell lymphoma. International journal of hematology, 110(3), 263-264. https://doi.org/10.1007/s12185-019-02695-x
Karube, Kennosuke, and Todoroki, Jumpei. "Sinus-confined involvement pattern of mantle cell lymphoma." International journal of hematology vol. 110,3 (2019): 263-264. doi: https://doi.org/10.1007/s12185-019-02695-x
Karube K, Todoroki J. Sinus-confined involvement pattern of mantle cell lymphoma. Int J Hematol. 2019 Sep;110(3):263-264. doi: 10.1007/s12185-019-02695-x. Epub 2019 Jul 09. PMID: 31289998.
Copy Download .nbib Format: NLM
Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group.

American journal of hematology

Weisenburger DD, Vose JM, Greiner TC, Lynch JC, Chan WC, Bierman PJ, Dave BJ, Sanger WG, Armitage JO.
PMID: 10861815
Am J Hematol. 2000 Jul;64(3):190-6. doi: 10.1002/1096-8652(200007)64:3<190::aid-ajh9>3.0.co;2-b.

Although mantle cell lymphoma (MCL) is considered a distinctive disease entity within non-Hodgkin's lymphoma (NHL), the cytology and growth pattern of MCL can be quite variable and the clinical significance of these features is unclear. Also, the role of...

Cite
Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol. 2000;64(3):190-6doi: 10.1002/1096-8652(200007)64:3<190::aid-ajh9>3.0.co;2-b.
Weisenburger, D. D., Vose, J. M., Greiner, T. C., Lynch, J. C., Chan, W. C., Bierman, P. J., Dave, B. J., Sanger, W. G., & Armitage, J. O. (2000). Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. American journal of hematology, 64(3), 190-6. https://doi.org/10.1002/1096-8652(200007)64:3<190::aid-ajh9>3.0.co;2-b
Weisenburger, D D, et al. "Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group." American journal of hematology vol. 64,3 (2000): 190-6. doi: https://doi.org/10.1002/1096-8652(200007)64:3<190::aid-ajh9>3.0.co;2-b
Weisenburger DD, Vose JM, Greiner TC, Lynch JC, Chan WC, Bierman PJ, Dave BJ, Sanger WG, Armitage JO. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol. 2000 Jul;64(3):190-6. doi: 10.1002/1096-8652(200007)64:3<190::aid-ajh9>3.0.co;2-b. PMID: 10861815.
Copy Download .nbib Format: NLM
Smoldering mantle cell lymphoma.

Journal of experimental & clinical cancer research : CR

Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, Wang ML.
PMID: 29246179
J Exp Clin Cancer Res. 2017 Dec 15;36(1):185. doi: 10.1186/s13046-017-0652-8.

BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a...

Cite
Ye H, Desai A, Zeng D, et al. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res. 2017;36(1):185doi: 10.1186/s13046-017-0652-8.
Ye, H., Desai, A., Zeng, D., Nomie, K., Romaguera, J., Ahmed, M., & Wang, M. L. (2017). Smoldering mantle cell lymphoma. Journal of experimental & clinical cancer research : CR, 36(1), 185. https://doi.org/10.1186/s13046-017-0652-8
Ye, Haige, et al. "Smoldering mantle cell lymphoma." Journal of experimental & clinical cancer research : CR vol. 36,1 (2017): 185. doi: https://doi.org/10.1186/s13046-017-0652-8
Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, Wang ML. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res. 2017 Dec 15;36(1):185. doi: 10.1186/s13046-017-0652-8. PMID: 29246179; PMCID: PMC5732450.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries